Rina Lokaj

Articles

Study shows 177Lu-PSMA-617 is noninferior to cabazitaxel in post-chemo mCRPC

January 3rd 2024

Data from the phase 2 TheraP trial showed that 177Lu-PSMA-617 induced comparable overall survival outcomes as cabazitaxel in patients with metastatic castration-resistant prostate cancer who progressed after receiving docetaxel.

Focal therapy associated with improved QOL in non-metastatic prostate cancer

December 22nd 2023

Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.

Do not sell my Personnal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777